Fiducial Legal by Lamy, Jones Day, Duteil Avocats and McDermott Will & Emery advised on the operation.
MaaT Pharma announced an €18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Crédit Mutuel Innovation, and Biocodex. The funding will enable the continued clinical development of the company’s current pipeline, as well as the expansion into additional oncological indications where restoring a functional microbiome could provide significant therapeutic benefit when combined with other cancer treatments such as immune checkpoint inhibitors.
The proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (NCT03359980) of MaaT’s lead compound, MaaT013, in patients that developed steroid-refractory, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR aGvHD) following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT).
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases.
Fiducial Legal by Lamy advised Seventure Partners with the help of Misha Raznatovich and Clotilde Mouchel
Jones Day advised SymBiosis LLC with Anne Kerneur and Renaud Bonnet.
Duteil Avocats advised Crédit Mutuel Innovation with Benoît Lespinasse.
McDermott Will & Emery advised MaaT Pharma with Laetitia de Dinechin, Emmanuelle Trombe (Picture) and Guillaume Beal.
Involved fees earner: Benoît Lespinasse – Duteil Avocats; Clotilde Mouchel – Fiducial Legal By Lamy; Misha Raznatovich – Fiducial Legal By Lamy; Renaud Bonnet – Jones Day; Anne Kerneur – Jones Day; Guillaume Beal – McDermott Will & Emery; Laetitia de Dinechin – McDermott Will & Emery; Emmanuelle Trombe – McDermott Will & Emery;